Cell Reports Medicine, Journal Year: 2023, Volume and Issue: 4(2), P. 100936 - 100936
Published: Jan. 23, 2023
Vaccine effectiveness of BNT162b2 and CoronaVac against COVID-19-associated hospitalization moderate-to-severe disease due to SARS-CoV-2 Omicron BA.2 is studied from the 1.36 million doses administered 766,601 953,400 children aged 3-11 years adolescents 12-18 in Hong Kong as April 2022. These vaccines confer substantial protection.
Language: Английский
JAMA Pediatrics, Journal Year: 2023, Volume and Issue: 177(4), P. 384 - 384
Published: Jan. 23, 2023
Evidence of the efficacy and safety messenger RNA (mRNA) COVID-19 vaccines in children aged 5 to 11 years has been emerging. Collecting these data will inform clinicians, families, policy makers.To evaluate mRNA a systematic review meta-analysis.PubMed Embase databases were searched on September 29, 2022, without language restrictions.Randomized clinical trials observational studies comparing vaccinated vs unvaccinated reporting or outcomes included. Studies only (ie, no control group) also included.Two investigators independently extracted relevant from each study. Odds ratios (ORs) for incidences adverse events (AEs) following vaccination synthesized using random-effects model. This study followed Preferred Reporting Items Systematic Reviews Meta-analyses Meta-analysis Observational Epidemiology guidelines.The primary outcome was SARS-CoV-2 infections with symptoms. The secondary included symptomatic infections, hospitalizations, multisystem inflammatory syndrome children. AE evaluated.Two randomized 15 involving 10 935 541 (median mean age range, 8.0-9.5 years) 2 635 251 7.0-9.5 Two-dose compared associated lower risks symptoms (OR, 0.47; 95% CI, 0.35-0.64), 0.53; 0.41-0.70), hospitalizations 0.32; 0.15-0.68), 0.05; 0.02-0.10). Two investigated AEs among Most experienced at least 1 local first injection (32 494 55 959 [86.3%]) second (28 135 46 447 [86.3%]). Vaccination higher risk any placebo 1.92; 1.26-2.91). incidence that prevented normal daily activities 8.8% (95% 5.4%-14.2%) myocarditis estimated be 1.8 per million 0.000%-0.001%) injection.In this meta-analysis, measures preventing infection severe COVID-19-related illnesses. While most developed AEs, rare, resolved within several days. These provide evidence future recommendations.
Language: Английский
Citations
62
The Lancet Child & Adolescent Health, Journal Year: 2023, Volume and Issue: 7(6), P. 379 - 391
Published: April 18, 2023
Language: Английский
Citations
55
Frontiers in Cellular and Infection Microbiology, Journal Year: 2023, Volume and Issue: 13
Published: June 29, 2023
Each infectious disease has had its own epidemic pattern and seasonality for decades. However, public health mitigation measures during the coronavirus 2019 (COVID-19) pandemic have resulted in changing patterns of diseases. Stringent low incidences various diseases outbreak COVID-19, including influenza, respiratory syncytial virus, pneumococcus, enterovirus, parainfluenza. Owing to prevalence severe acute syndrome 2 (SARS-CoV-2) infections subsequent immunity development, decreasing virulence SARS-CoV-2, worldwide immunization against SARS-CoV-2 children beyond 6 months age, are lifted country by country. Consequently, debt viruses other than contributed “off-season,” “see-saw,” “upsurge” children. Moreover, apart from persistence coexistence circulating or bacterial outbreaks may lead twindemics tripledemics following years. Therefore, it is necessary maintain hand hygiene policies pathogens alleviate ongoing impact on
Language: Английский
Citations
49
PEDIATRICS, Journal Year: 2024, Volume and Issue: 153(4)
Published: Jan. 16, 2024
Vaccination reduces the risk of acute coronavirus disease 2019 (COVID-19) in children, but it is less clear whether protects against long COVID. We estimated vaccine effectiveness (VE) COVID children aged 5 to 17 years.
Language: Английский
Citations
29
Annals of Internal Medicine, Journal Year: 2024, Volume and Issue: 177(2), P. 165 - 176
Published: Jan. 8, 2024
The efficacy of the BNT162b2 vaccine in pediatrics was assessed by randomized trials before Omicron variant's emergence. long-term durability protection this population during period remains limited.
Language: Английский
Citations
16
The Lancet Infectious Diseases, Journal Year: 2022, Volume and Issue: 23(4), P. 421 - 434
Published: Dec. 12, 2022
Language: Английский
Citations
55
BMJ evidence-based medicine, Journal Year: 2023, Volume and Issue: 28(3), P. 164 - 174
Published: March 31, 2023
To assess the benefits and drawbacks of school closures in-school mitigations during COVID-19 pandemic.Overview systematic reviews (SRs).We searched six databases additional resources on 29 July 2022: MEDLINE, Embase, Google Scholar, Cochrane Library, COVID-END inventory evidence synthesis, Epistemonikos.We selected SRs written in English that answered at least one four specific questions concerning efficacy closures. Their primary studies were conducted secondary schools, including pupils aged 5-18. Interventions included or (such as mask usage) introduced schools.We used AMSTAR 2 to confidence SRs, GRADE was certainty evidence. We performed a narrative synthesis results, prioritising higher-quality those which assessments with more unique studies. also assessed overlap between SRs.Our framework for summarising outcome data guided by following questions: (1) What is impact transmission, morbidity mortality community? (2) mental health (eg, anxiety), physical obesity, domestic violence, sleep) learning/achievement pupils? (3) schools (4) health, pupils?We identified 578 reports, 26 included. One SR high confidence, 0 moderate, 10 low 15 critically confidence. 132 effects transmission/morbidity/mortality, 123 learning, 164 22 16 sleep, 7 violence 69 transmission/morbidity/mortality.Both associated reduced community. School increased anxiety obesity pupils. found no potential The according mostly very low.School had both positive negative impacts. large number However, low, low. assessing children, could be addressed moving forward. This overview provides inform policy makers future waves COVID-19.
Language: Английский
Citations
30
The Lancet Child & Adolescent Health, Journal Year: 2023, Volume and Issue: 7(7), P. 463 - 470
Published: May 16, 2023
Language: Английский
Citations
25
Communications Medicine, Journal Year: 2023, Volume and Issue: 3(1)
Published: Jan. 5, 2023
Abstract Background The SARS-CoV-2 Omicron BA.2 subvariant replaced BA.1 globally in early 2022, and caused an unprecedented tsunami of cases Hong Kong, resulting the collapse elimination strategy. Vaccine effectiveness (VE) BNT162b2 CoronaVac against is unclear. Methods We utilize ecological design incorporating population-level vaccine coverage statistics territory-wide case-level infection surveillance data, investigate VE during wave between January 1 to April 19, Kong for children adolescents. Results estimate be 33.0% dose aged 5–11 40.8% 2 doses 3–11. also 54.9% BNT162b2, 55.0% adolescents 12–18. Conclusions Our findings support partly preserved by variants concerns settings with extremely low levels prior circulation.
Language: Английский
Citations
23
European Journal of Pediatrics, Journal Year: 2024, Volume and Issue: 183(3), P. 1107 - 1112
Published: Jan. 2, 2024
Abstract Countries in Europe and around the world have taken varying approaches to their policies on COVID-19 vaccination for children. The low risk of severe illness from means that even small risks warrant careful consideration. Vaccination appears result a decreased including paediatric multi-system inflammatory syndrome known be associated with COVID-19. These already significantly emergence Omicron variant its subvariants, due widespread population immunity through previous infection. There is relatively high myocarditis following second doses mRNA vaccines adolescent males, although general course this condition mild. Conclusion : only provides transient reduction transmission. Currently, insufficient evidence exists determine impact post-acute COVID syndromes children, which are uncommon. What Known: • Vaccines against reduced morbidity mortality world. Whilst countries universally recommended adults continue recommend them vulnerable populations, there has been more variability recommendations New: In setting near universal existing infection, majority initial benefit protecting eroded. children low, but an important consideration given modest benefits.
Language: Английский
Citations
10